Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidine.
Pseudoisocytidine (psi ICyd) is a C-nucleoside with enhanced stability and resistance to enzymatic deamination when compared to 5-azacytidine and 1-beta-D-arabinofuranosylcytosine. Elimination kinetics in plasma using [14C]psi ICyd showed a beta-phase for t1/2 for 14C of 2 hr and a beta-phase t1/2 of unchanged psi ICyd of 1.5 hr. Net recovery of radioactivity in urine over 24 hr varied between 40 and 80% of the administered dose; 50 to 90% was unchanged drug and the rest was pseudouridine. Human leukemic cells in vitro deaminated psi ICyd very slowly, formed appreciable quantities of pseudoisocytidine triphosphate, and incorporated small amounts into RNA and DNA. Clinical trials were done using a daily i.v. injection for 5 consecutive days. Hematological or intestine toxicities were not seen, nor was depression of white blood cell count observed in leukemic patients. Hepatic toxicity proved to be dose limiting; this was characterized by an early phase with elevation of prothrombin time and aspartate aminotransferase. A later phase with cirrhosis was observed in two patients. Autopsy showed massive hepatic necrosis in patients dying of acute toxicity and micronodular cirrhosis in one patient dying with the chronic form.
D000970:Antineoplastic Agents; D002478:Cells, Cultured; D003562:Cytidine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000378:metabolism; D008099:Liver / Q000187:drug effects; D008657:Metabolic Clearance Rate
D000970:Antineoplastic Agents; D003562:Cytidine; C012518:pseudoisocytidine